Total pendapatan perusahaan Zevra Therapeutics, Inc. (ZVRA)

Lambang korporat lan logo Zevra Therapeutics Inc (ZVRA)

The promising business of Zevra Therapeutics (ZVRA) relies on the success of Miplyffa and royalties from ADHD treatments. The company's sales volume dynamics demonstrate a current trend, where 0.15 describes the current status of the metric. The model operates through the full outsourcing of drug production to third-party vendors. Strong pricing power is ensured by inelastic demand for unique medications used to treat rare genetic pathologies.

ZVRA - Pendapatan perusahaan Zevra Therapeutics, Inc. ing rentang 28.04.2023 - 17.11.2026

Rincian analitis perusahaan zevra.com (ZVRA)

- rega saham lan prakiraan rega para ahli:
Analisis umum perusahaan:Zevra Therapeutics (ZVRA)
Produk seri Zevra Therapeutics

Sales reflect the daily cash inflow from product realization compared to historical demand. An investor analyzes the Zevra Therapeutics (ZVRA) sales revenue chart on GURU.Markets to assess the business's resilience to inflationary risks. This metric's trend captures actual consumer activity. For Zevra Therapeutics (ZVRA), this indicator confirms the effectiveness of its proprietary development platform. Pricing power in the CNS orphan disease niche ensures stable revenue growth.